{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T15:08:45Z","timestamp":1790780925538,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,8,28]],"date-time":"2015-08-28T00:00:00Z","timestamp":1440720000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s00432-015-2026-y","type":"journal-article","created":{"date-parts":[[2015,8,27]],"date-time":"2015-08-27T05:55:55Z","timestamp":1440654955000},"page":"379-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":84,"title":["Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents"],"prefix":"10.1007","volume":"142","author":[{"given":"Kai","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan J.","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory","family":"Mavis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron S.","family":"Czuczman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,8,28]]},"reference":[{"key":"2026_CR1","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1038\/jid.2012.125","volume":"132","author":"N Al-Yacoub","year":"2012","unstructured":"Al-Yacoub N, Fecker LF, Mobs M, Plotz M, Braun FK, Sterry W, Eberle J (2012) Apoptosis induction by SAHA in cutaneous T-cell lymphoma cells is related to downregulation of c-FLIP and enhanced TRAIL signaling. J Invest Dermatol 132:2263\u20132274. doi: 10.1038\/jid.2012.125","journal-title":"J Invest Dermatol"},{"key":"2026_CR2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1158\/1078-0432.CCR-06-0914","volume":"13","author":"NB Arnold","year":"2007","unstructured":"Arnold NB, Arkus N, Gunn J, Korc M (2007) The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances gemcitabine-induced cell death in pancreatic cancer. Clin cancer res Off J Am Assoc Cancer Res 13:18\u201326. doi: 10.1158\/1078-0432.CCR-06-0914","journal-title":"Clin cancer res Off J Am Assoc Cancer Res"},{"key":"2026_CR3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/bcp.12048","volume":"76","author":"M Baluom","year":"2013","unstructured":"Baluom M, Grossbard EB, Mant T, Lau DT (2013) Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies. Br J Clin Pharmacol 76:78\u201388. doi: 10.1111\/bcp.12048","journal-title":"Br J Clin Pharmacol"},{"key":"2026_CR4","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat rev Drug discov 5:769\u2013784. doi: 10.1038\/nrd2133","journal-title":"Nat rev Drug discov"},{"key":"2026_CR5","doi-asserted-by":"crossref","first-page":"e79781","DOI":"10.1371\/journal.pone.0079781","volume":"8","author":"S Chen","year":"2013","unstructured":"Chen S, Zhao Y, Gou WF, Zhao S, Takano Y, Zheng HC (2013) The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells. PLoS One 8:e79781. doi: 10.1371\/journal.pone.0079781","journal-title":"PLoS One"},{"key":"2026_CR6","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1158\/1078-0432.CCR-07-1254","volume":"14","author":"MS Czuczman","year":"2008","unstructured":"Czuczman MS et al (2008) Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels. Clin Cancer Res Off J Am Assoc Cancer Res 14:1561\u20131570. doi: 10.1158\/1078-0432.CCR-07-1254","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2026_CR7","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J clin oncol off j Am Soc Clin Oncol 28:4184\u20134190. doi: 10.1200\/JCO.2010.28.1618","journal-title":"J clin oncol off j Am Soc Clin Oncol"},{"key":"2026_CR8","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/B978-0-12-394387-3.00006-9","volume":"116","author":"S Grant","year":"2012","unstructured":"Grant S, Dai Y (2012) Histone deacetylase inhibitors and rational combination therapies. Adv Cancer Res 116:199\u2013237. doi: 10.1016\/B978-0-12-394387-3.00006-9","journal-title":"Adv Cancer Res"},{"key":"2026_CR9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/bjh.12452","volume":"162","author":"JJ Gu","year":"2013","unstructured":"Gu JJ, Hernandez-Ilizaliturri FJ, Kaufman GP, Czuczman NM, Mavis C, Skitzki JJ, Czuczman MS (2013) The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br J Haematol 162:657\u2013669. doi: 10.1111\/bjh.12452","journal-title":"Br J Haematol"},{"key":"2026_CR10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00280-013-2220-z","volume":"72","author":"M Iwamoto","year":"2013","unstructured":"Iwamoto M, Friedman EJ, Sandhu P, Agrawal NG, Rubin EH, Wagner JA (2013) Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol 72:493\u2013508. doi: 10.1007\/s00280-013-2220-z","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026_CR11","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.leukres.2012.02.021","volume":"36","author":"S Kewitz","year":"2012","unstructured":"Kewitz S, Bernig T, Staege MS (2012) Histone deacetylase inhibition restores cisplatin sensitivity of Hodgkin\u2019s lymphoma cells. Leuk Res 36:773\u2013778. doi: 10.1016\/j.leukres.2012.02.021","journal-title":"Leuk Res"},{"key":"2026_CR12","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4161\/cc.4.4.1564","volume":"4","author":"PA Marks","year":"2005","unstructured":"Marks PA, Jiang X (2005) Histone deacetylase inhibitors in programmed cell death and cancer therapy. Cell Cycle 4:549\u2013551","journal-title":"Cell Cycle"},{"key":"2026_CR13","doi-asserted-by":"crossref","unstructured":"Marks PA, Richon VM, Kelly WK, Chiao JH, Miller T (2004) Histone deacetylase inhibitors: development as cancer therapy. Novartis foundation symposium 259:269\u2013281, discussion 281\u2013268","DOI":"10.1002\/0470862637.ch20"},{"key":"2026_CR14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/1535370213498985","volume":"238","author":"SA Maxwell","year":"2013","unstructured":"Maxwell SA, Mousavi-Fard S (2013) Non-Hodgkin\u2019s B-cell lymphoma: advances in molecular strategies targeting drug resistance. Exp Biol Med 238:971\u2013990. doi: 10.1177\/1535370213498985","journal-title":"Exp Biol Med"},{"key":"2026_CR15","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1038\/onc.2013.482","volume":"33","author":"A Newbold","year":"2013","unstructured":"Newbold A, Salmon JM, Martin BP, Stanley K, Johnstone RW (2013) The role of p21 and p27 in HDACi-mediated tumor cell death and cell cycle arrest in the Emu-myc model of B-cell lymphoma. Oncogene 33:5415\u20135423. doi: 10.1038\/onc.2013.482","journal-title":"Oncogene"},{"key":"2026_CR16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1128\/MCB.18.1.629","volume":"18","author":"AB Niculescu 3rd","year":"1998","unstructured":"Niculescu AB 3rd, Chen X, Smeets M, Hengst L, Prives C, Reed SI (1998) Effects of p21(Cip1\/Waf1) at both the G1\/S and the G2\/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 18:629\u2013643","journal-title":"Mol Cell Biol"},{"key":"2026_CR17","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1158\/1078-0432.CCR-07-1255","volume":"14","author":"SH Olejniczak","year":"2008","unstructured":"Olejniczak SH, Hernandez-Ilizaliturri FJ, Clements JL, Czuczman MS (2008) Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res Off J Am Assoc Cancer Res 14:1550\u20131560. doi: 10.1158\/1078-0432.CCR-07-1255","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"2026_CR18","first-page":"1705","volume":"40","author":"PS Ong","year":"2012","unstructured":"Ong PS, Wang XQ, Lin HS, Chan SY, Ho PC (2012) Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells. Int J Oncol 40:1705\u20131713. doi: 10.3892\/ijo.2012.1354","journal-title":"Int J Oncol"},{"key":"2026_CR19","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.3892\/or.2014.3008","volume":"31","author":"C Park","year":"2014","unstructured":"Park C et al (2014) Momilactone B induces apoptosis and G1 arrest of the cell cycle in human monocytic leukemia U937 cells through downregulation of pRB phosphorylation and induction of the cyclin-dependent kinase inhibitor p21Waf1\/Cip1. Oncol Rep 31:1653\u20131660. doi: 10.3892\/or.2014.3008","journal-title":"Oncol Rep"},{"key":"2026_CR20","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1128\/MCB.14.3.1669","volume":"14","author":"D Resnitzky","year":"1994","unstructured":"Resnitzky D, Gossen M, Bujard H, Reed SI (1994) Acceleration of the G1\/S phase transition by expression of cyclins D1 and E with an inducible system. Mol Cell Biol 14:1669\u20131679","journal-title":"Mol Cell Biol"},{"key":"2026_CR21","first-page":"29","volume":"60","author":"NS Saba","year":"2012","unstructured":"Saba NS, Levy LS (2012) Protein kinase C-beta inhibition induces apoptosis and inhibits cell cycle progression in acquired immunodeficiency syndrome-related non-Hodgkin lymphoma cells Journal of investigative medicine : the official publication of the American Federation for. Clin Res 60:29\u201338. doi: 10.231\/JIM.0b013e318237eb55","journal-title":"Clin Res"},{"key":"2026_CR22","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00277-013-1787-0","volume":"93","author":"P Savini","year":"2014","unstructured":"Savini P, Lanzi A, Foschi FG, Marano G, Stefanini GF (2014) Lenalidomide monotherapy in relapsed primary cutaneous diffuse large B cell lymphoma-leg type. Ann Hematol 93:333\u2013334. doi: 10.1007\/s00277-013-1787-0","journal-title":"Ann Hematol"},{"key":"2026_CR23","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD (2015) Jemal A (2015) Cancer statistics. CA Cancer J Clin 65:5\u201329. doi: 10.3322\/caac.21254","journal-title":"CA Cancer J Clin"},{"key":"2026_CR24","doi-asserted-by":"crossref","first-page":"e62822","DOI":"10.1371\/journal.pone.0062822","volume":"8","author":"RC Thompson","year":"2013","unstructured":"Thompson RC, Vardinogiannis I, Gilmore TD (2013) The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS One 8:e62822. doi: 10.1371\/journal.pone.0062822","journal-title":"PLoS One"},{"key":"2026_CR25","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1038\/leu.2013.224","volume":"28","author":"KK Wong","year":"2014","unstructured":"Wong KK et al (2014) Reciprocal expression of the endocytic protein HIP1R and its repressor FOXP1 predicts outcome in R-CHOP-treated diffuse large B-cell lymphoma patients. Leukemia 28:362\u2013372. doi: 10.1038\/leu.2013.224","journal-title":"Leukemia"},{"key":"2026_CR26","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3109\/10428194.2013.806800","volume":"55","author":"C Zang","year":"2014","unstructured":"Zang C, Eucker J, Liu H, Coordes A, Lenarz M, Possinger K, Scholz CW (2014) Inhibition of pan-class I phosphatidyl-inositol-3-kinase by NVP-BKM120 effectively blocks proliferation and induces cell death in diffuse large B-cell lymphoma. Leuk lymphoma 55:425\u2013434. doi: 10.3109\/10428194.2013.806800","journal-title":"Leuk lymphoma"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-2026-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-015-2026-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-015-2026-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T18:08:26Z","timestamp":1567102106000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-015-2026-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,28]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["2026"],"URL":"https:\/\/doi.org\/10.1007\/s00432-015-2026-y","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,28]]}}}